Patient-Derived immune Xenograft Core2020-11-27T11:52:19+00:00

Patient-Derived immune Xenograft Core

The Patient-Derived immune Xenograft (PDiX) core is funded by the CRUK City of London Centre based at the UCL Cancer Institute. The facility provides training tools and techniques for the generation of PDX models that contain T cell and other immune cells present in the patient’s tumor microenvironment. These models will be used in the evaluation of current and novel immunotherapy agents and combination therapies. PDiX systems are generated in immunocompromised mouse models through the implantation of tumour fragments from patient samples.

The core will also provide a detailed outline of the process for procuring fresh patient tissue (biobank or clinical trial samples), sample preparation, in vivo techniques, and flow cytometry for detecting donor immune cells. The facility also provides training in short-term patient-derived explants in vitro to allow users to observe changes in immune landscape with targeted therapy if limited on sample size and quality.

Please see the Immune Regulation and Tumour Immunotherapy Group page to learn more about our research.

Contact

Dr Mansi Shah
Dr Mansi Shah PDiX Specialist

Academic Lead

Professor Sergio Quezada
Professor Sergio Quezada Group Leader: Immune Regulation and Tumour Immunotherapy Lab

Workflow

To generate PDiX, your University/facility should provide:

  • Animal Facility to house NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) colony
  • Home Office Project license to allow minor surgeries (for more details please contact PDiX Specialist)
  • Risk assessments to work with Human tissue
  • HTA and GDPR certificates to handle human tissue
  • Flow cytometry facility

Services

The core can provide detailed SOPs to process and isolate PBMCs (peripheral blood mononuclear cells), TILs (tumour infiltrating lymphocytes), tumour fragments for PDiX.

The core can provide training on implanting tumour fragments into mouse models (minor surgery involved), treating mice with drug/biotheraptic therapies and processing tissue for end-of experiment analysis.

Additional services can be provided for training users to observe changes in tumour immune landscape using high-dimensional flow cytometry.

On-going collaborations

  • Head and Neck cancers PDiX/explants in collaboration with Dr. Martin Forster, Professor Tony Ng and Roche
  • Colorectal cancers PDiX/explants in collaboration with Professor John Bridgewater and Dr. Manuel Justo-Rodriguez (UCL Cancer Institute)
  • Lung cancer cancer PDiX/explants in collaboration with TRACERx Consortium
  • Multiple Myeloma PDiX/explants in collaboration with Professor Kwee Yong

Please see the Immune Regulation and Tumour Immunotherapy Group page to learn more about our research.